Show simple item record

dc.contributor.authorCox, E
dc.contributor.authorSaramago, P
dc.contributor.authorKelly, J
dc.contributor.authorPorta, N
dc.contributor.authorHall, E
dc.contributor.authorTan, WS
dc.contributor.authorSculpher, M
dc.contributor.authorSoares, M
dc.date.accessioned2020-08-05T14:37:47Z
dc.date.accessioned2020-09-30T14:16:35Z
dc.date.issued2020-08-01
dc.identifier.citationClinical genitourinary cancer, 2020, 18 (4), pp. e418 - e442
dc.identifier.issn1558-7673
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4111
dc.identifier.eissn1938-0682
dc.identifier.doi10.1016/j.clgc.2019.12.004
dc.description.abstractBACKGROUND: Limited evidence exists regarding the cost and health-related quality of life (HRQoL) effects of non-muscle-invasive bladder cancer (NMIBC) recurrence and progression to muscle-invasive bladder cancer (MIBC). We examined these effects using evidence from a recent randomized control trial. MATERIAL AND METHODS: The costs and HRQoL associated with bladder cancer were assessed using data from the BOXIT trial (bladder COX-2 inhibition trial; n = 472). The cost and HRQoL effects from clinical events were estimated using generalized estimating equations. The costs were derived from the recorded resource usage and UK unit costs. HRQoL was assessed using the EQ-5D-3L and reported UK preference tariffs. The events were categorized using the TMN classification. RESULTS: Cases of grade 3 recurrence and progression were associated with statistically significant HRQoL decrements (-0.08; 95% confidence interval [CI], -0.13 to -0.03; and -0.10; 95% CI, -0.17 to -0.03, respectively). The 3-year average cost per NMIBC patient was estimated at £8735 (95% CI, 8325-9145). Cases of grade 1, 2, and 3 recurrence were associated with annual cost effects of £1218 (95% CI, 403-2033), £1677 (95% CI, 920-2433), and £3957 (95% CI, 2332-5583), respectively. Progression to MIBC was associated with an average increase in costs of £5407 (95% CI, 2663-8152). CONCLUSION: Evidence from the BOXIT trial suggests that patients with NMIBC will both experience decrements in HRQoL and incur significant costs, especially in the event of a grade 3 recurrence or a progression to MIBC.
dc.formatPrint-Electronic
dc.format.extente418 - e442
dc.languageeng
dc.language.isoeng
dc.publisherCIG MEDIA GROUP, LP
dc.relation.replaceshttps://repository.icr.ac.uk/handle/internal/3911
dc.relation.replacesinternal/3911
dc.relation.replacesinternal/3978
dc.relation.replaceshttps://repository.icr.ac.uk/handle/internal/3978
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleEffects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial.
dc.typeJournal Article
dcterms.dateAccepted2019-12-09
rioxxterms.versionofrecord10.1016/j.clgc.2019.12.004
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical genitourinary cancer
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.publication-statusPublished
pubs.volume18
pubs.embargo.termsNot known
icr.researchteamClinical Trials & Statistics Unit
icr.researchteamICR-CTSU Urology and Head and Neck Trials Team
dc.contributor.icrauthorPorta, Nuria
dc.contributor.icrauthorHall, Emma


Files in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0